Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 8,500 | |||
5 mg | 在庫あり | ¥ 13,500 | |||
10 mg | 在庫あり | ¥ 22,500 | |||
25 mg | 在庫あり | ¥ 40,500 | |||
50 mg | 在庫あり | ¥ 68,500 | |||
100 mg | 在庫あり | ¥ 104,500 | |||
200 mg | 在庫あり | ¥ 151,000 | |||
500 mg | 在庫あり | ¥ 226,500 |
説明 | DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. |
In vitro | DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer. |
In vivo | As determined by loss of body weight and death of treated mice,DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity[2]. |
別名 | N,N''-Carbonylbis[L-glutamic acid], (2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid |
分子量 | 320.25 |
分子式 | C11H16N2O9 |
CAS No. | 302941-52-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 280 mg/mL (874.32 mM)
H2O: 140 mg/mL (437.16 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DUPA 302941-52-2 Others PROTAC Ligands for Target Protein for PROTAC Target Protein-binding Moiety N,N''-Carbonylbis[L-glutamic acid] Inhibitor (2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid inhibit inhibitor